An In-Depth Review of Secretome Therapy Approaches in Medical Practice
Secretome Therapy in Medicine

Mohammad Ebrahimi

The Research Center for New Technologies in Life Science Engineering, Institute of Bio-signal and Immunculus, Tehran University, Tehran, Iran

Publication Date: 2025/02/25

Abstract: In recent years, cell transplantation strategies have shifted focus toward utilizing cell byproducts, particularly the cell secretome—a collection of proteins and bioactive molecules secreted by cells. Initially defined in the context of bacterial proteins, the concept of the secretome has expanded to encompass a wide range of biological systems, offering significant potential in medical applications. Secretome therapy, which leverages the regenerative properties of stem cell-derived factors, has emerged as a promising approach for tissue repair, disease treatment, and diagnostic innovation. The secretome's ability to reduce inflammation, promote tissue repair, and stimulate functional recovery positions it as a versatile tool in modern medicine. However, the translation of secretome therapy from preclinical studies to clinical practice faces several challenges, including issues of standardization, scalability, safety, regulatory compliance, and disease-specific optimization. By addressing these challenges through rigorous research, collaboration, and innovative solutions, secretome therapy can realize its full potential as a transformative treatment modality. This review underscores the importance of advancing our understanding of secretome biology and developing effective strategies to harness its therapeutic benefits, ultimately improving patient outcomes across a spectrum of medical conditions.

Keywords: *Cell Secretome**,** Secretome Therapy, Regenerative Medicine, Clinical Applications, Clinical Challenges.*

How to Cite: Mohammad Ebrahimi (2025) An In-Depth Review of Secretome Therapy Approaches in Medical Practice. *International Journal of Innovative Science and Research Technology*, 10(2), 539-544. https://doi.org/10.5281/zenodo.14949822

I. INTRODUCTION

In recent years, cell transplantation strategies have increasingly focused on utilizing cell byproducts, particularly the cell secretome. The term "secretome" was originally used to describe the proteins secreted by bacteria, particularly in the context of Bacillus subtilis. This concept emerged from efforts to predict which proteins could be secreted through a genome-wide analysis of the bacteria's genome. Initially, the definition focused solely on the proteins that bacteria release into their surroundings, derived from a thorough examination of their genetic structure. As research in proteomics progressed and expanded to include a variety of organisms, the definition of the secretome evolved to encompass a broader range of biological contexts. Agrawal et al. proposed a more comprehensive definition of the secretome in their review on the plant secretome. It is defined as "the complete collection of proteins secreted into the extracellular space (ECS) by a cell, tissue, organ, or organism at any given moment and under various conditions, utilizing both known and unknown secretory mechanisms involving constitutive and regulated secretory organelles." While this definition provides valuable insight, it is crucial to recognize that, so far, very few studies have identified more than 100 proteins within the secretome. As a result, we cannot yet assert that we have a truly "global" understanding of this complex biological landscape. This broader definition emphasizes the complexity and diversity of secreted proteins across different organisms and biological systems. The study of the secretome has emerged as a crucial area of research for understanding cell signaling and communication, disease mechanisms, and the development of potential diagnostic and therapeutic tools. The secretome encompasses a complex mixture of proteins, lipids, and other biologically active molecules secreted by cells, which play a vital role in communication and signaling between cells. These secreted molecules can serve various functions, including regulating cell growth, inflammation, and immune responses [1-3].

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14949822

II. SECRETOME THERAPY IN MEDICAL PRACTICE

In medical practice, the secretome is important for several reasons:

A. Biomarker Discovery:

The secretome comprises a diverse array of proteins and biologically active molecules that can serve as biomarkers for various diseases. Through the study of the secretome, researchers are able to identify specific biomarkers that may reveal disease states or indicate how effectively a patient is responding to treatment [4-7].

B. Diagnostic Tools:

Analyzing the secretome can offer valuable insights into the health of cells and tissues. For instance, by studying the secretome of cancer cells, researchers may be able to create diagnostic tools for the early detection of cancer [8-10].

C. Therapeutic Potential:

The secretome holds promise as a source of therapeutic agents. Secretome therapy is an innovative approach that utilizes the regenerative potential of secreted factors—such as proteins, growth factors, and cytokines—from stem cells to promote tissue repair and regeneration. The secretome contains a complex mix of bioactive molecules that can have various therapeutic effects on different parts of the body. Positive outcomes from different types of secretome have been observed in conditions affecting the skin, cartilage, bones, kidneys, cardiovascular and nervous system, helping to accelerate recovery by replacing damaged or non-functional tissues through the differentiation and regeneration of cells.

III. THERAPEUTIC POTENTIAL OF SECRETOME THERAPY

The secretome derived from stem cells has demonstrated the ability to enhance wound healing, decrease inflammation, and stimulate collagen production in the skin. This makes it beneficial for treating conditions such as burns, scars, and skin ageing. Secretome therapy has demonstrated promise in addressing kidney injuries and diseases by aiding the repair of damaged kidney tissues and enhancing kidney function. It can also help reduce inflammation and fibrosis in the kidneys. Stem cell-derived secretome has been shown to significantly improve cardiac function, stimulate angiogenesis, and minimize scar tissue formation in the heart following a myocardial infarction. Furthermore, it plays a protective role by shielding cardiac cells from damage, thereby supporting overall heart health and recovery. These effects are supported by scientific evidence, highlighting the therapeutic potential of stem cell secretome in cardiac repair and regeneration. Secretome therapy possesses neuroprotective and neuroregenerative properties that can benefit conditions such as stroke, spinal cord injury, and neurodegenerative diseases. It aids in promoting nerve cell survival, enhancing neural repair, and improving functional recovery. Moreover, secretome therapy has been shown to stimulate the regeneration of cartilage and bone tissues, making it a potential treatment for conditions like osteoarthritis, fractures, and bone defects. It can promote cartilage repair, reduce inflammation, and enhance bone formation [11-18].

The secretome contains factors that can either promote or inhibit cancer cell growth, depending on the context. Some studies suggest that secretome derived from cancer cells may stimulate tumor growth and metastasis, while secretome from normal cells can inhibit cancer cell growth and induce apoptosis. The precise role of the secretome in cancer is still under investigation [19-23].

The secretome can influence the environment where stem cells exist in the body by modifying the microenvironment around them. Stem cells are unique cells with the ability to self-renew and differentiate into different types of cells. The niche is a specialized environment that provides important signals and support to keep stem cells functioning properly and to prevent them from differentiating prematurely. When there is a dysfunction in the components of the stem cell niche, it can affect the activity of stem cells and potentially lead to challenging chronic or acute disorders [24-26].

The secretome includes a diverse array of signaling factors that can impact the stem cell niche. These factors consist of:(1) Growth factors, cytokines, chemokines, and extracellular matrix proteins derived from conditioned medium, (2) Small molecules, such as metabolites, microvesicles, and exosomes, (3) Cell organelles, like mitochondria. Some of these factors foster processes like stem cell proliferation, differentiation, and survival, while others may inhibit these functions. For instance, fibroblast growth factor (FGF) and bone morphogenetic proteins (BMPs) are growth factors that encourage both the proliferation and differentiation of stem cells. FGF also plays a role in angiogenesis, the formation of new blood vessels, which is crucial for tissue repair and regeneration. Meanwhile, BMPs promote bone formation by stimulating mesenchymal stem cells to differentiate into osteoblasts [27-29].

Conversely, transforming growth factor beta (TGF-β) and Prostaglandin E2 (PGE2) are signaling molecules that can inhibit stem cell proliferation and differentiation. TGF-β may induce stem cell quiescence, a dormant state that prevents excessive cell division and differentiation. PGE2 helps inhibit inflammation and protects against tissue damage, which is vital for maintaining stem cell function in the body [30-31].

The composition of the secretome plays a crucial role in determining the behavior of stem cells. It can influence whether stem cells remain in a quiescent state or become activated, whether they proliferate or differentiate, and whether they contribute to tissue repair or regeneration. Gaining a deeper understanding of the secretome's role in stem cell biology could have significant implications for regenerative medicine and tissue engineering, paving the way for more effective therapies and advancements in these fields.

- *Extracellular Vehicles:*

Extracellular vesicles (EVs) are tiny, membrane-enclosed particles that cells release into their surrounding environment. These remarkable structures act as messengers, transporting a diverse array of molecular cargo—such as proteins, lipids, and nucleic acids—between cells, enabling vital communication. EVs are broadly categorized into three main types: exosomes, microvesicles, and apoptotic bodies, each playing unique roles in cellular interactions and biological processes. Extracellular vesicles (EVs) play a crucial role in numerous physiological processes, including facilitating cell-to-cell communication, regulating immune responses, and influencing the progression of various diseases. Due to their unique properties, researchers are actively exploring their potential as innovative therapeutic tools for delivering drugs and genetic material directly to target cells. The secretome, which encompasses EVs along with other bioactive molecules, is thought to enhance intercellular communication, interact with neighboring cells, and transfer functional biomolecules that can trigger tissue repair and regeneration. Overall, studies have shown that the secretome exhibits various beneficial properties, including promoting new blood vessel formation, preventing cell death, antifibrotic, anti-inflammatory, modulating immune responses, and encouraging cell growth [32-35].

IV. OPTIMAL ROUTE OF ADMINISTRATION FOR SECRETOMES

The most effective method for delivering secretomes as a therapeutic intervention in humans has yet to be established, as research in the field of secretome-based therapies is still in its early stages. The choice of administration route will depend on several factors, including the specific syndrome being treated, the size and composition of the secretomes, and target site. Intravenous (IV) injection is a widely used method for delivering secretomes, as it allows for systemic distribution throughout the body. However, one drawback of IV administration is that it can lead to rapid clearance and degradation of secretomes by the liver and kidneys, potentially limiting their effectiveness. Alternative routes of administration that have been explored in preclinical studies include intranasal, intratumoral, and local injections into affected tissues or organs. Intranasal administration offers a direct delivery pathway to the central nervous system (CNS), which could be beneficial for treating conditions like Alzheimer's or Parkinson's disease and Sudden Sensorineural Hearing Loss (SSHL). On the other hand, intratumoral injection directly targets tumors, potentially promoting tumor cell death or inhibiting tumor growth, which could be advantageous in cancer therapy. Ultimately, the choice of administration route will depend on the specific application and will require further clinical evaluation to ensure safety and efficacy in humans [36-39].

V. CHALLENGES FACING SECRETOME THERAPY

Secretome therapy, a cutting-edge approach that involves using the secreted products of stem cells to treat diseases, has demonstrated promising results in preclinical studies. However, applying this therapy in practical medicine comes with its share of challenges. This review seeks to summarize the existing scientific evidence regarding the obstacles faced by secretome therapy and to highlight potential solutions for overcoming these issues.

- *Standardization and Consistency:*

The composition of secretomes can vary considerably depending on factors such as the type of stem cells, culture conditions, and processing techniques. To ensure reliable and reproducible outcomes, it is crucial to establish standardized protocols for secretome preparation and maintain consistent dosing. This approach not only enhances the reliability of research but also paves the way for safe and effective therapeutic applications [40-41].

- *Scalability and Cost-Effectiveness:*

For secretome therapy to be practical in medicine, it is crucial to produce high-quality secretomes on a large scale. However, the current challenges related to the cost and scalability of secretome production pose significant obstacles to its widespread use Forming partnerships between academic institutions, research organizations, and the biotechnology industry can facilitate resource sharing, funding, and expertise, ultimately advancing the scalability and affordability of secretome therapy [42-43].

- *Extraction and Refinement of Bioactive Molecules:*

Isolating and purifying bioactive molecules from secretomes is a challenging and labor-intensive endeavor. To guarantee their effectiveness in therapy, it is essential to establish streamlined and efficient techniques for extracting and purifying these valuable compounds [44-45].

- *Safety and Efficacy Concerns:*

The safety and efficacy of secretome therapy are still under investigation. It is important to address concerns related to immune reactions, tumor growth, and off-target effects through thorough preclinical and clinical testing. During clinical trials, vigilant monitoring of patients for immune responses is essential. By assessing biomarkers associated with immune activation, researchers can identify any increased risk of adverse reactions early on. Additionally, collaborating with immunologists, oncologists, and other specialists can deepen our understanding of the potential risks

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14949822

linked to secretome therapy and lead to comprehensive strategies for mitigating these risks [46-48].

➢ *Regulatory Framework:*

The lack of a clear regulatory framework for secretome therapy hinders its adoption in clinical practice. Regulatory agencies need to establish guidelines for the development, testing, and approval of secretome-based therapies [49].

➢ *Delivery Methods:*

Effective delivery methods for secretomes are crucial for achieving therapeutic efficacy. The development of targeted delivery systems that can efficiently deliver secretomes to specific tissues or organs is essential [50].

➢ *Disease-Specific Applications:*

Secretome therapy holds promise for a wide range of diseases, with its applications potentially varying depending on the specific condition being treated. To fully unlock its therapeutic potential, further research and clinical trials are essential to develop disease-specific secretomes and tailor treatment protocols accordingly. This personalized approach could enhance the efficacy of secretome-based therapies, ensuring they are optimized to address the unique biological and pathological mechanisms of each disease [51-52].

➢ *Patient Selection and Monitoring:*

Patient selection and monitoring are critical for ensuring the safety and efficacy of secretome therapy. Development of biomarkers and monitoring protocols is necessary to identify suitable patients and track treatment outcomes. Genetic variability among individuals can impact how their cells produce and respond to secretomes. Certain genetic profiles may result in variations in the bioactive molecules present in the secretome, influencing therapeutic effectiveness. Epigenetic modifications, which affect gene expression without altering the DNA sequence, can also play a crucial role in how cells respond to external cues, including those from secretomes. These modifications can influence the activity of signaling pathways and the overall response to therapy [53-54].

While secretome therapy holds significant promise for treating various diseases, several challenges must be addressed before it can be widely adopted in practical medicine. Addressing these challenges will require further research, collaboration between scientists, clinicians, and industry stakeholders, and a commitment to developing effective regulatory frameworks.

VI. CONCLUSION

In conclusion, the therapeutic potential of secretome therapy is undeniable, with numerous studies showcasing its effectiveness in treating a variety of diseases and conditions. However, it is crucial to acknowledge the complexities and limitations that accompany these approaches. The intricate nature of secretome biology, along with the interplay of intrinsic and extrinsic factors, must be carefully considered in the development of treatments. Moreover, a thorough understanding of the complexities inherent in both stem cell therapy and secretome therapy is vital for creating effective strategies that fully harness their potential. As this field continues to advance, it is essential to emphasize rigorous research, critically assess existing data, and foster collaboration among researchers. By doing so, we can enhance our comprehension of these therapies and ultimately improve outcomes for patients.

Conflict of Interest: Authors have no conflict of interest.

REFERENCES

[1]. Tjalsma H, Bolhuis A, Jongbloed JD, Bron S, Van Dijl JM (2000) Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome Microbiol. Mol. Biol. Rev. 64 (2000): 515-547.

[2]. Erik A, Ashfaq A, Svante R and Erik A (2013) Plant secretome proteomics. Front Plant Sci 4(9)1-6.

[3]. Pinho AG, Cibrão JR, Silva NA, Monteiro S, and Salgado AJ (2020) Cell Secretome: Basic Insights and Therapeutic Opportunities for CNS Disorders. Pharmaceuticals (Basel). 13(2): 1-18.

[4]. Stastna M and Van Eyk JE (2012) Secreted proteins as a fundamental source for biomarker discovery. Proteomics. 12(4-5): 722–735.

[5]. Makridakis M, Vlahou A (2010) Secretome proteomics for discovery of cancer biomarkers. J Proteomics 73:2291–2305.

[6]. Celis JE, Gromov P, Cabezon T, Moreira JM, Sandelin K, et al (2004) Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 3:327–344.

[7]. Raimondo F, Morosi L, Chinello C, Magni F, et al (2011) Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics. 11:709–720.

[8]. Wei W and Jeroen K (2024) Secretome Analysis: Reading Cellular Sign Language to Understand Intercellular Communication. Mol Cell Proteomics. 23(1): 1-19.

[9]. Mustafa S, Pan L, Marzoq A, Fawaz M, Sander L, Rückert F, et al (2017) Comparison of the Tumor Cell Secretome and Patient Sera for an Accurate Serum-Based Diagnosis of Pancreatic Ductal Adenocarcinoma. Oncotarget. 8:11963–11976.
[10]. Fijneman RJA, de Wit M, Pourghiasian M, Piersma SR, Pham TV, Warmoes MO, et al (2012) Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer. Clin. Cancer Res. 18:2613–2624.
[11]. Udalamaththa VL, Kaluarachchi A, Wijeratne S and Udagama PV (2020) Therapeutic uses of post-partum tissue-derived mesenchymal stromal cell secretome. Indian J Med Res. 152(6): 541–552.
[12]. Fei T, Xuran L, Zhao W, Jiaojiao L, Khawar S and Jialin Z (2024) Clinical applications of stem cell-derived exosomes. Signal Transduction and Targeted Therapy. 9(17):1-31
[13]. Ranganath SH, Levy O, Inamdar MS, Karp JM (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 10:244–58.
[14]. Liu B, Ding F, Hu D, Zhou Y, Long C, Shen L, et al (2018). Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-κB signaling pathway in vivo and in vitro. Stem Cell Res Ther. 9(7):1-14.
[15]. Jafarinia M, Alsahebfosoul F, Salehi H, Eskandari N, Azimzadeh M, Mahmoodi M, et al (2020) Therapeutic effects of extracellular vesicles from human adipose-derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis. Journal of cellular physiology. 235:8779–90.
[16]. Konala VB, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R (2016) The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration. Cytotherapy. 18:13–24.
[17]. Sukmawati TT, Putri BA, Yohanes F, Nathasia N, Erwin B, Siufui H (2023) Effectiveness of Secretome from Human Umbilical Cord Mesenchymal Stem Cells in Gel (10% SM-hUCMSC Gel) for Chronic Wounds (Diabetic and Trophic Ulcer) – Phase 2 Clinical Trial. Journal of Multidisciplinary Healthcare. 16 :1763–177.
[18]. Müller T (2021) Viewpoint: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track? Biologics: Targets and Therapy. 15: 307–316.
[19]. Ritchie S, Reed DA, Pereira BA and Timpson P (2021). The cancer cell secretome drives cooperative manipulation of the tumour microenvironment to accelerate tumourigenesis. Fac Rev. 10(4):1-14.
[20]. Karagiannis GS, Pavlou MP, Diamandis EP (2010) Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol. 4(6): 496–510.
[21]. Brandi J, Manfredi M, Speziali G, Fabio G, Emilio M, Daniela C (2018) Proteomic approaches to decipher cancer cell secretome. Semin Cell Dev Biol. 78: 93–101.
[22]. Alidoust M, Lahiji S, Safari F (2022) Potential therapeutic effects of hAMSCs secretome on Panc1 pancreatic cancer cells through downregulation of SgK269, E-cadherin, vimentin, and snail expression. Biologicals. 76: 24-30.
[23]. Ferenc S, Györgyi M (2022) Disagreements in the therapeutic use of mesenchymal stem cell derived secretome. World J Stem Cells. 14(6): 365-371.
[24]. Palmer TD, Willhoite AR, and Gage FH (2000) Vascular niche for adult hippocampal neurogenesis. J. Comp. Neurol. 425: 479–494.
[25]. Sagaradze G, Monakova A, Basalova N, Popov V, Balabanyan V and Efimenkoa A (2022) Regenerative medicine for male infertility: A focus on stem cell niche injury models. Biomed J. 45(4): 607–614.
[26]. Salgado AJ, Pires AO, Pinto L, Sousa N, Mateus-Pinheiro A, Teixeira FG, et al (2015) Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities. Front Cell Neurosci. 9(249):1-18.
[27]. Fadilah NIMD, Abdul Kader Jailani MSM, Iqmal Badrul Hisham MA, Raj NS, Shamsuddin SA, Min Hwei Ng, et al (2022) Cell secretomes for wound healing and tissue regeneration: Next generation acellular based tissue engineered products. Journal of Tissue Engineering.13: 1–21.
[28]. Jayaraman P, Nathan P, Vasanthan P, Sabri M, Vijayendran G (2013) Stem cells conditioned medium: a new approach to skin wound healing management. Cell Biol Int. 37: 1122–1128.
[29]. Mintz PJ, Huang K-W, Reebye V, Nteliopoulos G, Lai HS, Sætrom P, et al (2014) Exploiting human CD34+ stem cell-conditioned medium for tissue repair. Mol Ther. 22: 149–159.
[30]. Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, et al (2016). Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 7:1-11.
[31]. González-González A, García-Sánchez D, Dotta M, Rodríguez-Rey JC, PérezCampo FM (2020) Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine. World J Stem Cells. 12(12): 1529-1552.
[32]. Yáñez-Mó M, Siljander PRM, Andreu Z, Zavec AB, Borràs FE, Buzas EI, et al (2015) Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles. 4: 1-60.

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14949822

[33]. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al (2006) Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 20:847-856.
[34]. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C (2005) Exosomal-like vesicles are present in human blood plasma. Int Immunol. 17:879-887.
[35]. Poliakov A, Spilman M, Dokland T, Amling CL, Mobley JA (2009) Structural heterogeneity and protein composition of exosome-like vesicles (prostasomes) in human semen. Prostate. 69:159-167.
[36]. Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML and Corsico AG (2020) Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use. Cells. 9(4): 1-5.
[37]. Amodeo G, Niada S, Moschetti G, Franchi S, Savadori P, Brini AT, Sacerdot P (2021) Secretome of human adipose-derived mesenchymal stem cell relieves pain and neuroinflammation independently of the route of administration in experimental osteoarthritis. Brain, Behavior, and Immunity. 94: 29-40.
[38]. Ranya I, Hillary M, Pradeep K, Samson AA and Yahya EC (2022) Cell Secretome Strategies for Controlled Drug Delivery and Wound-Healing Applications. Polymers (Basel). 14(14): 1-20.
[39]. Li F, Zhang J, Yi K, Wang H, Wei H, Chan HF, Tao Y, Li M (2022) Delivery of Stem Cell Secretome for Therapeutic Applications. ACS Appl. Bio Mater. 5: 2009–2030.
[40]. Chouaib B, Haack-Sørensen M, Chaubron F, Cuisinier F and Collart-Dutilleul PY (2023) Towards the Standardization of Mesenchymal Stem Cell Secretome-Derived Product Manufacturing for Tissue Regeneration. Int J Mol Sci. 24(16): 1-15.
[41]. Hsiao ST, Asgari A, Lokmic Z, Sinclair R, Dusting GJ, Lim SY, Dilley RJ (2012) Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev. 21: 2189–2203.
[42]. Fábio G. Teixeira, and António J. Salgado (2020). Mesenchymal stem cells secretome: current trends and future challenges. Neural Regen Res. 15(1): 75–77.
[43]. Phelps J, Sanati-Nezhad A, Ungrin M, Duncan NA and Sen A (2018) Bioprocessing of Mesenchymal Stem Cells and Their Derivatives: Toward Cell-Free Therapeutics. Stem Cells International. 2018:1-24.
[44]. Truong NM, Tran DX, Hoang-Dung T, Truong MV, Yusuf A, Tran DK, et al (2019) Isolation and Purification of Bioactive Compounds from the Stem Bark of Jatropha podagrica. Molecules. 24(5): 1-15.
[45]. Caseiro AR, Pedrosa SS, Ivanova G, Branquinho MV, Almeida A, Faria F, et al (2019) Mesenchymal Stem/ Stromal Cells metabolomic and bioactive factors profiles: A comparative analysis on the umbilical cord and dental pulp derived Stem/ Stromal Cells secretome. PLoS ONE. 14(11):1-33.
[46]. Giovannelli L, Bari E, Jommi C, Tartara F, Armocida D, Diego Garbossa D, et al (2023) Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: Risk-benefit profile and next steps for the market access. Bioact Mater. 29: 16–35.
[47]. Bascones-Martinez A, Mattila R, Gomez-Font R, Meurman JH (2014) Immunomodulatory drugs: Oral and systemic adverse effects. Med. Oral Patol. Oral Cir. Bucal. 19: e24–e31.
[48]. Zhao Q, Ren H, Han Z (2016) Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases. J. Cell. Immunother. 2:3–20.
[49]. Bauer SR (2004) Stem Cell-based Products in Medicine: FDA Regulatory Considerations. Handbook of Stem Cells. 2004: 805–814.
[50]. Abd. Kakhar U (2023) Stem Cell's Secretome Delivery Systems. Adv Pharm Bull.13(2): 244–258.
[51]. Tran C and, Damaser MS (2015). Stem cells as drug delivery methods: Application of stem cell secretome for regeneration. Advanced Drug Delivery Reviews. 82(83):1-11.
[52]. Chukwuweike G, Nequesha M, Xue M (2021) Stem cell secretome, regeneration, and clinical translation: a narrative review. Ann Transl Med. 9(1):1-11.
[53]. Tuz Zohora F, Aliyu M and Saboor-Yaraghi AA (2023) Secretome-based acellular therapy of bone marrow-derived mesenchymal stem cells in degenerative and immunological disorders: A narrative review. Heliyon. 9(7): 1-20.
[54]. Liang-Yun C, Ting-Wan K, Chang-Cyuan C, Noreen N, Hsin-Lun L, Yu-Hsin, et al (2023) Frontier Review of the Molecular Mechanisms and Current Approaches of Stem Cell-Derived Exosomes. Cells. 12(7): 1-29.